<DOC>
	<DOCNO>NCT00608972</DOCNO>
	<brief_summary>The purpose research study look effectiveness combination doxil , carboplatin bevacizumab metastatic breast cancer . The type breast cancer study negative protein call HER2/neu estrogen receptor ( ER ) progesterone receptor ( PR ) . HER2/neu , ER PR part family receptor find cancer normal cell . This family receptors important cell growth find many tumor types.This study conduct follow research purpose : · To find effect , , study drug metastatic breast cancer . For instance , study drug cause tumor ( ) shrink stop grow ? · To test safety study drug see affect . For instance , side effect ? If , kind side effect study drug cause ? How severe side effect , often occur ? · To see study drug effect keep disease get bad .</brief_summary>
	<brief_title>Phase II Trial Doxil , Carboplatin , Bevacizumab Triple Negative Untreated Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Women previously untreated metastatic breast cancer , ER/PR/HER2/neu negative . 2 . Age &gt; = 18 3 . ECOG performance status &lt; = 2 4 . Normal organ marrow function 5 . Normal cardiac function evidence LVEF within institutional normal limit 1 . History hypersensitivity reaction doxil bevacizumab 2 . Myocardial infarct unstable angina within 6 month enrollment 3 . Prior anthracycline dose exceed 360 mg/m2 doxorubicin ( include DOXIL ) 720 mg/m2 epirubicin . 4 . Proteinuria</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>negative protein call HER2/neu</keyword>
	<keyword>negative estrogen receptor ( ER ) progesterone receptor ( PR ) .</keyword>
	<keyword>breast cancer</keyword>
</DOC>